FASCINATE THERAPEUTICS
FAScinate is a clinical-stage company that develops disease-modifying drugs for neurodegenerative diseases such as Parkinson's disease (PD) and multiple system atrophy (MSA).
FASCINATE THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2018-01-01
Status:
Active
Contact:
(858) 630-8540
Email Addresses:
[email protected]
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Fast Access Specialty Therapeutics
Fast Access Specialty Therapeutics is a specialty pharmacy company.
Syndya Therapeutics
Syndya Therapeutics is a 3D combinatorial, phenotypic screening company.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-02-15 | Egret Therapeutics | FAScinate Therapeutics investment in Seed Round - Egret Therapeutics | N/A |
More informations about "FAScinate Therapeutics"
FAScinate Therapeutics - Crunchbase Investor Profile
Legal Name FAScinate Therapeutics, Inc. Investor Type Private Equity Firm, Venture Capital Contact Email [email protected]; Phone Number (858) 630-8540; FAScinate is a clinical-stage company that develops …See details»
About Us - fascinatetherapeutics.com
FAScinate is a clinical stage company that develops disease-modifying drugs for neurodegenerative diseases such as Parkinson’s disease (PD) and multiple system atrophy (MSA). FAScinate Therapeutics was founded in 2018 as a …See details»
FAScinate Therapeutics Company Profile 2025: …
FAScinate Therapeutics General Information Description. Developer of novel drugs and therapeutics intended to treat Parkinson's disease. The company develops drugs for neurodegenerative diseases such as multiple system …See details»
FAScinate Therapeutics - VentureRadar
FAScinate Therapeutics Follow Following Location: USA. Founded in 2018. Privately Held " FAScinate is a clinical stage company that develops disease-modifying drugs for …See details»
Fascinate Therapeutics , Inc. - Drug pipelines, Patents, Clinical ...
Clinical Trials associated with Fascinate Therapeutics , Inc. NCT05670782 / Active, not recruiting Phase 2. A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and …See details»
Organization | FAScinate Therapeutics Inc. - Purdue University
Organization Overview. First Clinical Trial. 2022 NCT05670782. First Marketed Drug. None First NDA Approval. None Last Known Activity ... FAScinate Therapeutics Inc. Active Ingredients. …See details»
FAScinate Therapeutics - Investments, Portfolio & Company Exits
Feb 15, 2022 FAScinate Therapeutics has invested in Egret Therapeutics on Feb 15, 2022. How many investments has this organization made over time? Show . Which industries has this …See details»
FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical Trials of ...
Nov 17, 2021 FDA Approves FAScinate’s Application for Phase 2 Trials with “KM-819” Treatment . SAN DIEGO (PRWEB) NOVEMBER 17, 2021 Clinical stage drug development …See details»
Fascinate Therapeutics Company Profile -Sales, Contacts, …
Fascinate Therapeutics is located in San Diego, California. This organization primarily operates in the Biotechnical Research, Commercial business / industry within the Engineering, …See details»
FAScinate Therapeutics - Updates, News, Events, Signals & Triggers
Feb 15, 2022 FAScinate Therapeutics invests in seed-stage biotechnology and healthcare companies, focusing on therapeutics. Their investment strategy is centered in New York, …See details»
KM-819 for the Treatment of Parkinson’s Disease ... - CND Life …
FAScinate Therapeutics announces positive Phase 2 trial results for KM-819, a promising treatment for Parkinson’s, showing potential neuroprotective effects. ... Sara supports strategic …See details»
KM-819 - Drug Targets, Indications, Patents - Synapse - Patsnap
Dec 27, 2024 FDA Approves FAScinate’s Application for Phase 2 Trials with “KM-819” Treatment SAN DIEGO (PRWEB) NOVEMBER 17, 2021 Clinical stage drug development …See details»
Briana Bohae Lee - Business Director - Fascinate Therapeutics, Inc ...
Business Director at FAScinate Therapeutics, Inc. · Experience: Fascinate Therapeutics, Inc. · Education: 연세대학교 / Yonsei University · Location: San Diego · 261 connections on LinkedIn.See details»
Durham's Tune Therapeutics raises $175M in venture capital
14 hours ago Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for …See details»
FAScinate Therapeutics Inc Submits Investigational New Drug (IND ...
Nov 2, 2021 FAScinate Therapeutics today announced that it has submitted an Investigational New Drug (IND) Application for Phase 2 clinical trials of its Parkinson's Disease drug …See details»
Partnerships - fascinatetherapeutics.com
As KM-819 proceeds through clinical trials, we’re seeking investment and development partners to help change the future of treatment for neurodegenerative conditions like Parkinson’s …See details»
Nurix Therapeutics Outlines 2025 Goals and Objectives for …
1 day ago SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, …See details»
FAScinate Therapeutics - Tech Stack, Apps, Patents & Trademarks
FAScinate Therapeutics is actively using the technology U.S. Server Location for its website, according to BuiltWith. UNLOCK PREMIUM DATA WITH DATABOOST IT Spend by …See details»
News/Publications - fascinatetherapeutics.com
Nov 17, 2021 FAScinate Therapeutics Completes Part 1a of Phase 2 Study of Company's Parkinson’s Disease Drug Candidate "KM-819" Read Now > Thursday, January 12, 2023 / …See details»
Akebia Therapeutics Announces Multiple Positive Business Updates
1 day ago Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced multiple …See details»